Genmab/$GMAB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Genmab
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Ticker
$GMAB
Sector
Primary listing
Employees
2,639
Headquarters
Copenhagen, Denmark
Website
Genmab Metrics
BasicAdvanced
$17B
1.25
$21.62
0.80
-
Price and volume
Market cap
$17B
Beta
0.8
52-week high
$27.54
52-week low
$17.24
Average daily volume
1.3M
Financial strength
Current ratio
6.216
Quick ratio
6.196
Long term debt to equity
2.49
Total debt to equity
2.791
Interest coverage (TTM)
49.22%
Profitability
EBITDA (TTM)
1,327.422
Gross margin (TTM)
94.54%
Net profit margin (TTM)
37.59%
Operating margin (TTM)
34.95%
Effective tax rate (TTM)
11.77%
Revenue per employee (TTM)
$1,380,000
Management effectiveness
Return on assets (TTM)
13.26%
Return on equity (TTM)
28.12%
Valuation
Price to earnings (TTM)
1.253
Price to revenue (TTM)
0.469
Price to book
20.15
Price to tangible book (TTM)
33.44
Price to free cash flow (TTM)
1.62
Free cash flow yield (TTM)
61.71%
Free cash flow per share (TTM)
16.712
Growth
Revenue change (TTM)
32.97%
Earnings per share change (TTM)
77.72%
3-year revenue growth (CAGR)
31.40%
10-year revenue growth (CAGR)
40.59%
3-year earnings per share growth (CAGR)
31.80%
10-year earnings per share growth (CAGR)
33.13%
What the Analysts think about Genmab
Analyst ratings (Buy, Hold, Sell) for Genmab stock.
Bulls say / Bears say
Johnson & Johnson’s second-quarter Darzalex sales reached $3.54 billion, surpassing expectations and translating into robust royalty streams for Genmab. (Reuters)
Genmab reported positive Phase II results for Arzerra in chronic lymphocytic leukaemia, with overall response rates of 77% and no unexpected safety findings, bolstering its late-stage pipeline. (Reuters)
Shares jumped 26% on June 8 after a Danish newsletter raised the approval probability for zalutumumab from 25% to 80% and highlighted potential takeover interest from GSK, reflecting renewed investor optimism. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2025.
Genmab Financial Performance
Revenues and expenses
Genmab Earnings Performance
Company profitability
Genmab News
AllArticlesVideos
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Benzinga4 weeks ago
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
CNBC Television1 month ago
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
Business Wire3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Genmab stock?
Genmab (GMAB) has a market cap of $17B as of September 05, 2025.
What is the P/E ratio for Genmab stock?
The price to earnings (P/E) ratio for Genmab (GMAB) stock is 1.25 as of September 05, 2025.
Does Genmab stock pay dividends?
No, Genmab (GMAB) stock does not pay dividends to its shareholders as of September 05, 2025.
When is the next Genmab dividend payment date?
Genmab (GMAB) stock does not pay dividends to its shareholders.
What is the beta indicator for Genmab?
Genmab (GMAB) has a beta rating of 0.8. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.